

**DEAL PROFILE****AES Acquires Global Site Business from Bioclinica****AES**

Accelerated Enrollment Solutions (AES), a business unit of Pharmaceutical Product Development (PPD), established in 2018, offers sponsors and contract research organizations leading site conduct and patient access solutions. In recent years, AES has acquired Synexus to represent its site network, Acurian to represent its core patient enrollment services, and Optimal Research to represent its services in both vaccines and oncology. PPD is a leading global contract research organization providing comprehensive, integrated drug development, and laboratory and lifecycle management services. PPD has office locations in 48 countries and employs over 21,000 professionals worldwide.

**BIOCLINICA®****BIOCLINICA**

Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials, ultimately helping companies to develop new life-improving therapies more efficiently and safely. Bioclinica offers capabilities across the trial lifecycle supported by science and technology expertise. With over 135 drugs approved by the FDA and more than 4,000 clinical trials supported, Bioclinica offers deep insight into key areas of clinical development. Bioclinica is headquartered in Princeton, New Jersey, and employs over 2,800 professionals worldwide.

**BOURNE PARTNERS MARKET RESEARCH**

**Bourne Partners provides strategic and financial advisory services to clients throughout the business evolution life cycle. In order to provide the highest level of service, we routinely analyze relevant industry trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, OTC, consumer health, and biotechnology sectors.**

**OVERVIEW**

On September 5, 2019, Accelerated Enrollment Solutions, announced that it had acquired Bioclinica's Global Site Business. The transaction included research sites from the 2014 Bioclinica and CCBR-SYNARC merger. The addition of Bioclinica's Global Site Business advances AES' strategy of becoming the world's largest patient access and site conduct organization. Financial details were not disclosed.

**HIGHLIGHTS**

AES' acquisition of Bioclinica's Global Site Business extends its reach into new markets including China, Latin America and Western Europe, augmenting its leading presence in North America, Europe and South Africa. The fundamental components of the clinical trial supply chain, including sites, patient recruitment and fully consented data, align with AES' delivery model. AES' acquisition enables the company to set a new standard in clinical trial productivity with an extended global presence. This transaction also aligns with PPD / AES / Synexus' desire to acquire clinical research sites, as displayed by the company's 2017 acquisition of Optimal Research. Due to the highly fragmented landscape of the clinical research sites space, we believe the industry will likely see continued acquisitions of sites in the future.